Catalizadores heterogéneos a base de titania modificada con cerio o vanadio, caracterización y su aplicación para la síntesis de 2,3,5-trimetil-<i>p</i>-benzoquinona

En este trabajo se estudia la aplicación de materiales a base de cerio-titanio y vanadio titanio como catalizadores para la síntesis de 2,3,5-TMBQ, a partir de la oxidación de 2,3,6-trimetilfenol (2,3,6-TMF), en fase liquida, con H2O2 como oxidante limpio, y a baja temperatura. Los materiales fueron sintetizados vía sol-gel y se caracterizaron por técnicas fisicoquímicas (BET, XRD, FT-IR ,titulación potenciométrica). Se compara la actividad catalítica de los xerogeles 5CeTi y 5VTi, empleándolos en la reacción mencionada.Facultad de Ciencias Agrarias y Forestale

Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.

peer reviewed[en] OBJECTIVE: To analyze the safety and efficacy of niraparib in patients aged ≥70 years with recurrent ovarian cancer in the ENGOT-OV16/NOVA trial. METHODS: The trial enrolled 2 independent cohorts with histologically diagnosed recurrent ovarian, fallopian tube, or peritoneal cancer who responded to platinum rechallenge, on the basis of germline breast cancer susceptibility gene mutation (gBRCAmut) status. Patients were randomized 2:1 to receive niraparib (300 mg) or placebo once daily until disease progression. The primary endpoint was progression-free survival (PFS) by blinded independent central review. Adverse events (AEs) of special interest were based on the known safety profile of poly(ADP-ribose) polymerase inhibitors. RESULTS: Patients aged ≥70 years in the gBRCAmut cohort receiving niraparib (n = 14) had not yet reached a median PFS compared with a median PFS of 3.7 months for the same age group in the placebo arm (hazard ratio [HR], 0.09 [95% confidence interval (CI), 0.01 to 0.73]). Non-gBRCAmut patients aged ≥70 years receiving niraparib (n = 47) had a median PFS of 11.3 months compared with 3.8 months in the placebo arm (HR, 0.35 [95% CI, 0.18 to 0.71]). Median duration of follow-up in the niraparib arm was 17.3 months in patients ≥70 years and 17.2 months in patients <70 years. Frequency, severity of AEs, and dose reductions in the niraparib arm were similar in patients aged <70 and ≥ 70 years population. The most common grade ≥ 3 AEs in patients ≥70 years were hematologic: thrombocytopenia event (34.4%), anemia event (13.1%), and neutropenia event (16.4%). CONCLUSIONS: For patients ≥70 years of age receiving niraparib as maintenance treatment in the ENGOT-OV16/NOVA trial, PFS benefits and incidence of any grade or serious treatment-emergent AEs were comparable to results in the younger population. Use of niraparib should be considered in this population

Gestión del conocimiento. Perspectiva multidisciplinaria. Volumen 8

El libro “Gestión del Conocimiento. Perspectiva Multidisciplinaria”, volumen 8, de la Colección Unión Global, es resultado de investigaciones. Los capítulos del libro, son resultados de investigaciones desarrolladas por sus autores. El libro es una publicación internacional, seriada, continua, arbitrada de acceso abierto a todas las áreas del conocimiento, que cuenta con el esfuerzo de investigadores de varios países del mundo, orientada a contribuir con procesos de gestión del conocimiento científico, tecnológico y humanístico que consoliden la transformación del conocimiento en diferentes escenarios, tanto organizacionales como universitarios, para el desarrollo de habilidades cognitivas del quehacer diario. La gestión del conocimiento es un camino para consolidar una plataforma en las empresas públicas o privadas, entidades educativas, organizaciones no gubernamentales, ya sea generando políticas para todas las jerarquías o un modelo de gestión para la administración, donde es fundamental articular el conocimiento, los trabajadores, directivos, el espacio de trabajo, hacia la creación de ambientes propicios para el desarrollo integral de las instituciones

A square two-dimensional polymer of cobalt citrate cubanes

5 páginas, 4 figuras, 2 tablas.The structure of the title complex, poly[dicaesium(I) hexaaquacobalt(II) [octaaquatetra--citrato-hexacobalt(II)] dodecahydrate], {Cs2[Co(H2O)6][Co6(C6H4O7)4(H2O)8]·12H2O}n, at 100 (1) K is formed by layers of a square two-dimensional polymer composed of CoII citrate cubanes bridged by magnetically active six-coordinate CoII cations. The polymer has plane symmetry p4mm in the c-axis projection. The cubanes reside on sites of crystallographic symmetry , while the bridging CoII centres lie on twofold axes. The basic polymeric unit has a charge of 4-, balanced by two Cs+ and a [Co(H2O)6]2+ (symmetry ) cation, which lie in channels between the polymeric layers. Unligated water molecules, of which there are 12 per cubane, enter into an extended intralayer and layer-bridging hydrogen-bond pattern, which can be described in detail even though not all of the H atoms of the water molecules were located.This work was supported by the Ministry of Science and Innovation (Spain) under grant Nos. MAT2007-61621, MAT2008-04350 and CONSOLIDER-INGENIO in Molecular Nanoscience (reference CSD 2007-00010), and by the Diputación General de Aragón (Spain). EFV thanks the Ministry of Education (Spain) for a pre-doctoral scholarship under the programme ‘Becas y Contratos FPU’ (reference AP2009-4211)Peer reviewe

Mechanisms behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It

The introduction of trastuzumab therapy markedly improved the poor prognosis associated with HER2-amplified breast cancers. Despite this, the presence of primary and acquired resistance to trastuzumab treatment remains a significant common challenge. The identification of resistance mechanisms and the incorporation of new drugs that achieve a better blockade of HER family receptors signaling have resulted in improved outcomes. The phosphatidylinositol 3'-kinase/protein kinase B/mammalian target of rapamycin pathway, cross-talk with estrogen receptors, immune response, cell cycle control mechanisms, and other tyrosine kinase receptors such as insulin-like growth factor I receptor are potential pathways involved in trastuzumab resistance. Different therapeutic interventions targeting these pathways are currently under evaluation

Ordered magnetic arrays of cobalt SMM: properties and the relationship with crystal symmetry and SMM environment

Resumen del póster presentado a la 19th International Conference on Magnetism celebrada en Korea del 8 al 13 de julio de 2012.The modulation of the magnetic properties of SMMs and their organization in extended magnetic arrays are, at the present, some of the top areas in the field of molecular magnetism for the implication in the improvement of the physical properties of the SMM and the potential use in devices such as for data storage. Few polymers of SMM have been structurally characterized in spite of the number of known SMM. [Co4citrate4]8- cubanes can behave as SMM. We have reported recently the union of these cubanes through “Co(H2O)2ETG” (ETG=ethylene glycol) bridges and the formation of anionic 2D layers. These layers crystallize in the tetragonal system, P-421c space group, with counterions (Cs+ or Rb+), water and ETG molecules connecting the layers though electrostatic interactions and hydrogen bridges. The magnetic studies show the co-existence of two magnetic nets: the SMM net and the one formed by the bridged cobalt atoms and also shows the influence of the counterions in the layer magnetic properties. Two intriguing relaxation processes with different characteristics timescales are observed. Moreover, [Co4citrate4]8- cubanes can also organize in 3D, diamond-like structural arrays showing SMM magnetic behaviour below 6K with an enegry barrier of 54K and magnetic ordering below 2.7K.Peer reviewe

Metal hopping and reversible crystal transformation in a cobalt citrate SMM molecular solid

Trabajo presentado al 256th ACS National Meeting: "Nanoscience, Nanotechnology & Beyond", celebrado en Boston (US) del 19 al 23 de agosto de 2018.Peer Reviewe

A tetragonal 2D array of single-molecule magnets with modulated collective behavior

The counterion makes a difference: A square 2D array of cobalt citrate cubanes linked by bridging six-coordinate cobalt atoms (see graphic) displays collective magnetic behavior, which changes with subtle differences in the crystalline surroundings. The magnetic properties of two solid modifications, both synthesized by using wet chemistry techniques, reveal two different relaxation processes in each system at low temperatures, each with its own timescale.This work is supported by the Ministry of Science and Innovation (Spain) under grants MAT2007-61621, MAT2008-04350, and MAT2009- 13977-C03, CONSOLIDER-INGENIO in Molecular Nanoscience, ref. CSD 2007-00010, and by the Diputación General de Aragón (Spain).Peer Reviewe

Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA) : results from a double-blind, phase 3, randomised controlled trial

Background: Quality of life (QOL) has become an important complementary endpoint in cancer clinical studies alongside more traditional assessments (eg, tumour response, progression-free survival, overall survival). Niraparib maintenance treatment has been shown to significantly improve progression-free survival in patients with recurrent ovarian cancer. We aimed to assess whether the benefits of extending progression-free survival are offset by treatment-associated toxic effects that affect QOL. Methods: The ENGOT-OV16/NOVA trial was a multicentre, double-blind, phase 3, randomised controlled trial done in 107 study sites in the USA, Canada, Europe, and Israel. Patients with recurrent ovarian cancer who were in response to their last platinum-based chemotherapy were randomly assigned (2:1) to receive either niraparib (300 mg once daily) as a maintenance treatment or placebo. Randomisation was stratified based on time to progression after the penultimate platinum-based regimen, previous use of bevacizumab, and best response (complete or partial) to the last platinum-based regimen with permuted-block randomisation (six in each block) using an interactive web response system. The trial enrolled two independent cohorts on the basis of germline BRCA (gBRCA) mutation status (determined by BRACAnalysis Testing, Myriad Genetics, Salt Lake City, UT, USA). The primary endpoint of the trial was progression-free survival, and has already been reported. In this study, we assessed patient-reported outcomes (PROs) in the intention-to-treat population using the Functional Assessment of Cancer Therapy–Ovarian Symptoms Index (FOSI) and European QOL five-dimension five-level questionnaire (EQ-5D-5L). We collected PROs from trial entry every 8 weeks for the first 14 cycles and every 12 weeks thereafter. If a patient discontinued, we collected PROs at discontinuation and during a postprogression visit 8 weeks (plus or minus 2 weeks) later. We assessed the effect of haematological toxic effects on QOL with disutility analyses of the most common grade 3–4 adverse events (thrombocytopenia, anaemia, and neutropenia) using a mixed model with histology, region, previous treatment, age, planned treatment, and baseline score as covariates. This study is registered with ClinicalTrials.gov, number NCT01847274. Findings: Between Aug 28, 2013, and June 1, 2015, 553 patients were enrolled and randomly assigned to receive niraparib (n=138 in the gBRCAmut cohort, n=234 in the non-gBRCAmut cohort) or placebo (n=65 in the gBRCAmut cohort, n=116 in the non-gBRCAmut cohort). The mean FOSI score at baseline was similar between the two groups (range between 25·0–25·6 in the two groups). Overall QOL scores remained stable during the treatment and preprogression period in the niraparib group; no significant differences were observed between the niraparib and placebo group, and preprogression EQ-5D-5L scores were similar between the two groups in both cohorts (0·838 [0·0097] in the niraparib group vs 0·834 [0·0173] in the placebo group in the gBRCAmut cohort; and 0·833 [0·0077] in the niraparib group vs 0·815 [0·0122] in the placebo group in the non-gBRCAmut cohort). The most common adverse events reported at screening (baseline) were lack of energy (425 [79%]; 97 [18%] reporting severe lack of energy), pain (236 [44%]), and nausea (118 [22%]). All symptoms, except nausea, either remained stable or improved over time in the niraparib group. The most common grade 3 or 4 toxicities observed in the niraparib group were haematological in nature: thrombocytopenia (124 [34%] of 367 patients), anaemia (93 [25%]), and neutropenia (72 [20%]); disutility analyses showed no significant QOL impairment associated with these toxic effects. Interpretation: These PRO data suggest that women who receive niraparib as maintenance treatment for recurrent ovarian cancer after responding to platinum treatment are able to maintain QOL during their treatment when compared with placebo. Funding: TESARO